An Overview of Nogapendekin Alfa Inbakicept for High-Risk, BCG-Unresponsive NMIBC

EP: 1.Assessing Risk in NMIBC: A Foundation for Therapy

EP: 2.From Papillary to CIS: Tailoring NMIBC Treatment

EP: 3.Defining and Managing BCG-Unresponsive NMIBC

EP: 4.NMIBC Maintenance Therapy: Timing, Dosing, and Follow-Up

EP: 5.FDA-Approved Options for High-Risk BCG-Unresponsive NMIBC

EP: 6.An Overview Of Pembrolizumab for High-Risk BCG Unresponsive NMIBC

Now Viewing

EP: 7.An Overview of Nogapendekin Alfa Inbakicept for High-Risk, BCG-Unresponsive NMIBC

EP: 8.Real-World Outcomes With Nadofaragene in BCG-Unresponsive NMIBC

EP: 9.Exploring Nadofaragene Firadenovec: Ongoing Trials and Study Designs

EP: 10.Topline Results From Recent NMIBC Trials

Physician Summary:

Nogapendekin Alfa Inbakicept-pmln

• Mechanism of Action: Nogapendekin alfa is an immunotherapy that combines a recombinant protein designed to stimulate the immune system with the aim of inducing a localized immune response against bladder cancer cells, particularly for carcinoma in situ and papillary tumors. It acts by enhancing the body’s immune response to cancer cells, stimulating an inflammatory response that targets the tumor. This approach helps activate the immune system without requiring systemic exposure.
• Administration: Nogapendekin alfa is administered intravesically, with patients typically receiving the therapy directly into the bladder via catheter. After intravesical administration, it is followed by a course of intravesical BCG therapy, which further primes the immune response and increases efficacy by maintaining bladder immunity over time.

This combination approach offers a novel, dual immunotherapeutic strategy for BCG-unresponsive NMIBC, potentially enhancing both local and systemic immune responses to bladder cancer.